Thelansis

Chronic Thromboembolic Disease (CTED) Market Outlook Thelansis’s “Chronic Thromboembolic Disease (CTED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Thromboembolic Disease (CTED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the g...

  Chronic Thromboembolic Disease (CTED) Market Outlook Thelansis’s “Chronic Thromboembolic Disease (CTED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Thromboembolic Disease (CTED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Chronic Thromboembolic Disease (CTED) Overview Chronic thromboembolic disease (CTED) presents symptoms and perfusion defects similar to CTEPH but lacks PH at rest. A new threshold for PH diagnosis, defined as mean PAP (mPAP) >20 mmHg, along with criteria for pre-capillary PH (mPAP >20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg, and pulmonary vascular resistance (PVR) ≥3 Wood Units...

  Chronic thromboembolic disease (CTED) presents symptoms and perfusion defects similar to CTEPH but lacks PH at rest. A new threshold for PH diagnosis, defined as mean PAP (mPAP) >20 mmHg, along with criteria for pre-capillary PH (mPAP >20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg, and pulmonary vascular resistance (PVR) ≥3 Wood Units), has been established. Lung ventilation/perfusion scintigraphy is the preferred screening test, with a normal scan effectively ruling out CTEPH. CTEPH falls under group 4 PH and is pathologically characterized by organized thromboembolic material and altered vascular remodeling, influenced by defective angiogenesis, impaired fibrinolysis, and endothelial dysfunction. These changes precipitate PH, leading to right ventricular failure. While the exact pathogenesis remains unclear, acute pulmonary embolism is believed to trigger CTEPH, with documented antecedent history in patients. Several abnormal autoimmune, inflammatory, and thrombop...